Purine analogs are often used for conditioning preceding allogeneic hematopoietic stem cell transplantation (HCT). We prospectively tested fludarabine (Flu) 40 mg/m 2 / day Â 5 days vs cladribine (Clad) 10 mg/m 2 /day Â 5 days plus oral busulfan (1 mg/kg q6 h Â 2 days) and total body irradiation 200 cGy in 32 recipients of matched sibling and unrelated donor (URD) HCT. Patients were similar in age (median 52 years), diagnosis, extensive pre-HCT therapy (56 vs 63%), and high-risk disease status (81 vs 93%). Neutrophil engraftment was prompt (median 11 vs 12 days), but early graft failure using Clad halted randomization. Platelet recovery was prompt (median Flu 18 vs Clad 24 days). Graft-versus-host disease (GVHD) after Flu vs Clad was similar; (acute grade II/IV 56 vs 69%, P ¼ 0.26; chronic 50 vs 31%, P ¼ 0.27). Nonrelapse mortality (Flu 25 vs Clad 38%, P ¼ 0.47) and progression-free survival at 3 years were similar as well. Multivariate analyses showed slightly, but not significantly lower relative risk (RR) of neutrophil engraftment with Clad (RR 0.6 (95% CI 0.2-1.3) P ¼ 0.16) and with URD RR 0.4 (0.2-1.0) P ¼ 0.04). Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens.
Introduction
The ideal reduced intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) must induce sufficient immunosuppression to be permissive of an allograft, have limited multi-organ toxicity, and effect modest tumor cytoreduction. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Purine analogs have been widely used though differing purine analogs have not been compared. Their different immunosuppressive capacity and possible toxicity led us to prospectively test fludarabine (Flu) vs cladribine (Clad) along with busulfan and low-dose total body irradiation (TBI) as pretransplant conditioning follow allogeneic HCT.
Patients and methods
Thirty-two consecutive patients undergoing reduced intensity allogeneic related or unrelated donor transplantation at the University of Minnesota were enrolled in this randomized trial. Consenting patients were randomly assigned (without stratification) to either conditioning regimen in order to prospectively evaluate their comparative impact on engraftment as well as early and late mortality, graftversus-host disease (GVHD) and prevention of relapse. After an interim univariate analysis suggested inferiority of engraftment (and no possible superiority) in the Clad cohort, randomization was halted. An additional 15 consecutive patients received the Flu regimen to verify the initial experience. Details of their clinical characteristics are shown in Table 1 . Patients were eligible for reducedintensity transplantation if they were 455 years with related donors or 445 years with unrelated donors. Additionally eligible were those having received extensive prior therapy defined as: a prior autotransplant; 412 months alkylator-based chemotherapy; or 46 months alkylator-based chemotherapy plus extensive radiation; or those with compromised organ function or recent (within 4 months) invasive mold infection or compromised performance status (Karnofsky o70%). Before enrollment, all patients exercised written informed consent using documents reviewed and approved by the University of Minnesota Committee on the Use of Human Subjects in Research.
The randomly assigned (without stratification) treatment regimens were Flu 40 mg/m 2 daily for 5 days (days À5 to À1, total 200 mg/m 2 ) or Clad 10 mg/m 2 /day for 5 days (À5 to À1, total 50 mg/m 2 ). All patients also received busulfan 1 mg/kg orally four times daily for 2 days (total 8 mg/kg) and single-dose TBI 200 cGy on day À1. Cyclosporine planned for 6 months therapy and mycophenolate mofetil (MMF) scheduled to day þ 30 was administered beginning day À3.
All unrelated donors underwent unmobilized bone marrow harvest according to procedures specified by the National Marrow Donor Program. All related donors underwent G-CSF-mobilized peripheral blood progenitor collections targeting 5 Â 10 6 CD34 þ cells/kg recipient weight.
All patients were hospitalized in individual private rooms until neutrophil recovery and, if their clinical condition warranted, were then discharged for daily and subsequent frequent follow-up in the outpatient Bone Marrow Transplant Clinic. All patients received prophylactic antimicrobials directed towards fungal, bacterial, and viral pathogens as indicated by previous exposure or viral serostatus. Patients received conventional irradiated red cell and platelet transfusion support. Filgrastim 5 mg/kg/ day subcutaneously was administered from the onset of neutropenia (absolute neutrophil counto500/ml) until ANC 42500/ml for two consecutive days. Acute and chronic GVHD were diagnosed clinically and confirmed histologically when possible.
Statistical analysis
Comparisons of patient demographic characteristics were performed using w 2 (or Fisher's exact) testing and log-rank comparisons for continuous variables. The time to neutrophil engraftment (the first of three consecutive days with ANC 4500/ml), platelet recovery (450 000/ml for 7 days without required transfusion support), acute GVHD and chronic GVHD were calculated by the cumulative incidence method. 12 Graft failure was defined as no sustained neutrophil engraftment of donor origin by day þ 42. Progression-free and overall survival were calculated by Kaplan-Meier analyses 13 and multivariate analysis was performed using the Cox model using forward stepwise regression.
14 Variables considered in the regression included treatment assignment and demographics listed in Table 1 . Only variables with Po0.1 were retained in the model. As shown, acute GVHD was evaluated as a time dependent variable. Models were tested for proportional hazards and any interactions between variables. Owing to limited patient numbers, cautious interpretation of statistical significance was applied to results where Po0.05 but 40.01. The median follow-up of survivors was 40 months (range 23-47 months).
Immune recovery
Evaluation of potential differences in immunologic reconstitution was a secondary study end point. Circulating new thymic-derived T lymphocytes with T-cell receptor excision circles (TREC) were analyzed at varying time points, post transplant and reported as TREC
5 cells. Quantification of TREC in DNA of peripheral-blood mononuclear cells was performed by quantitative PCR as described. 15 Percentages of naive T cells with TREC in each CD4 or CD8 subset were measured by gating on CD45R0-negative, CD27-positive cells. Results for all available samples in time windows before and following HCT were calculated in the Flu (n ¼ 15) and Clad (n ¼ 14) treated cohorts.
Results
As shown in Table 1 , the 32 randomized patients had a median age 52. Approximately one-third had myeloid cancers and the others had lymphoid malignancies. Related donors and HLA-matched donors were more common in Table 2 Outcomes after non-ablative HCT: randomized patients the Flu group as was the use of G-CSF mobilized peripheral blood progenitor cells from related donors. Over 80% of patients had high-risk and very-high risk disease status and 41% had a prior autograft. The characteristics of the postrandomization cohort assigned to Flu were similar to the randomized patients.
Engraftment, GVHD, nonrelapse mortality and survival Clinical outcomes of the randomized patients are shown in Table 2 . Graft failure without autologous recovery in four patients occurred only in the Clad arm, though the median neutrophil engraftment time (12 and 11 days for Clad and Flu, respectively) was similar. Additionally, 69% Clad and 75% Flu patients had recovered platelets 450 000/ml by day þ 180. The median day to platelet recovery (450 000/ ml) was similar, but 6 days slower in the Clad cohort (median 24 vs 18 days, P ¼ 0.19). Both conditioning cohorts developed acute GVHD with similar incidence (Clad 69% and Flu 56% grade II-IV acute GVHD, P ¼ 0.26). The cumulative incidence of chronic GVHD was also similar in each group at 1 year follow-up. Nonrelapse mortality at 180 days (Flu 25 and Clad 38%, P ¼ 0.47) and survival (50% at 1 year in each cohort; Flu 38%, Clad 25% at 3 years, P ¼ 0.55) were similar using either conditioning regimen. The time-to-event curves reflecting these end points are shown in Figure 1 .
Though randomly assigned, multivariate modeling to compare efficacy of Flu vs Clad was used to adjust for differences in the patient population on neutrophil and platelet recovery and acute GVHD. As shown in Table 2 , failure of neutrophil and platelet recovery was more common in the URD cohort. However, in the multivariate model there was no statistically significant difference in either neutrophil or platelet recovery between the two randomized conditioning cohorts. Multivariate regression analysis demonstrated similar risks of acute GVHD for each treatment cohort (P ¼ 0.95). Acute GVHD was significantly more frequent in patients with very high disease risk status before transplantation (Po0.01).
Relapse and prevalence of response The relapse incidence was similar in both randomized cohorts, (cumulative incidence Flu 25% (5-45%) and Clad 38% (13-62%) at 3 years, P ¼ 0.53, Figure 2a ) and Fludarabine vs cladribine in allotransplantation M Markova et al progression-free survival was similar as well (25% at 3 years, P40.80, Figure 2b ). The durability of post transplant remission manifest as the prevalence of continuing remission in surviving patients was similar in both groups followed to 18 months post transplant. All (100%) Flu and 80% of surviving Clad patients remained in response (CR or PR without progression) at 36 months post transplantation.
Post transplant T-cell recovery
As Flu and Clad are intensely immunosuppressive and might have differential capacity to promote thymic injury and delay immune recovery, we tested circulating new thymus-derived T cells manifest as CD4 þ or CD8 þ T cells with T-cell receptor excision circles (TREC) over time. As shown in Figure 3, þ TREC and CD8 þ TREC levels remained below baseline. No differences in the pattern of recovery between the two randomized cohorts were seen.
Chimerism
Nearly all patients achieved complete donor-derived hematopoiesis and thus full hematopoietic chimerism. Sustained mixed chimerism was not observed. By 3 months 95% of Flu and 92% of Clad patients had X90% marrow donor chimerism. At 6 and 12 months, only one patient had o90% donor hematopoiesis.
Postrandomization enrollment
After interim results suggested no possible superiority for Clad in neutrophil engraftment recovery or acute GVHD, randomized enrollment was halted. An additional 15 patients were treated with the identical Flu conditioning regimen. Multivariate regression of the combined outcomes were similar to the original randomized cohort (Table 3 ). Neutrophil engraftment (Flu 100 vs Clad 75% (54-96%)), platelet recovery at 6 months (Flu 74% (59-94%) vs Clad 69% (43-95%)), acute GVHD, (Flu 48% (30-67) vs Clad 69% (42-96)), and day 180 nonrelapse mortality outcomes (Flu 23% (8-37%) vs Clad 25% (4-46)) were similar including the larger Flu cohort compared to the randomized Clad subset (all P40.07). Of the eligibility factors for reduced intensity conditioning (prior transplant, extensive prior therapy or defined comorbidities), only age X45 years was modestly associated with increased nonrelapse mortality (P ¼ 0.06), yet patients with only one of these four risk factors had notably lower nonrelapse mortality compared to those with two or more eligibility risk factors (data not shown). Similarly, survival estimates at 3 years (Clad (38%; 14-61%) and Flu (19%; 4-34%); P ¼ 0.35) showed no significant advantage for Clad on survival or in any end point. Multivariate regression (Table 3 ) demonstrated significantly better survival in patients o45 years, those without extensive pretreatment and those who did not develop severe acute GVHD (grade III/IV). Late disease progression was rare. As in the randomized group, at 36 months 80% of Clad and 100% of surviving Flu-conditioned patients continue without disease progression. For the combined group, the prevalence of response in surviving patients was 89% at 36 months.
Discussion
The increasingly widespread application of reduced intensity conditioning regimens for allotransplantation has allowed the potentially curative benefits of allografting to include older patients or those compromised by comorbid medical conditions which preclude safe application of conventional myeloablative grafting. The most widely used combinations of reduced intensity regimens include busulfan or melphalan plus nucleoside analogs, usually Flu, which are chosen for their antineoplastic and immunosuppressive capacities, respectively 2, 3 or Flu plus TBI. 4, 16 Recognizing the similar immunosuppressive capacity of Clad vs Flu to supplement the immunosuppressive potency of busulfan and low-dose TBI, we prospectively tested their comparative value. In adjusted regression analysis of the randomized trial we demonstrated slight, but not statistically significant improvement in engraftment with Flu, but observed overall similar outcomes including acute and chronic GVHD, nonrelapse mortality and survival. Our study halted enrollment to the Clad cohort early when interim analysis suggested it could not be superior, and might be associated with augmented risk of graft failure. Extended and risk-adjusted regression analysis confirmed non-superiority of Clad in this multiagent combination conditioning regimen. Additional factors were critical in predicting the outcome of reduced intensity allografts. As expected, transplants using unrelated donors had higher risks of graft failure, GVHD, and nonrelapse mortality, although net survival was similar for recipients of sibling or alternative donor grafting.
Reduced intensity transplantation was associated with promising control of underlying malignancy. As extended disease control in surviving patients may reflect ongoing graft vs tumor surveillance and prevention of progression, assessing the prevalence of response, including cancer regression associated with reduction in therapeutic immunosuppression may better describe the functional disease control of patients with persisting, yet stable disease after allografting. In survivors, we observed a continuing 92% prevalence of patients in response at 18 months follow-up suggesting the durability of antitumor effects, even using these limited intensity regimens. Similarly promising disease control has been reported with other combination reduced-intensity regimens. Baron et al. 16 reported modest risks of relapse and 39% 3 year progression-free survival in patients conditioned with Flu plus low-dose TBI. Flu plus alkylator (either intermediate-dose busulfan (4-8 mg/kg), cyclophosphamide or melphalan) has yielded promisingly low risks of disease progression and favorable disease-free survival (23-84%) as reported from MD Anderson Cancer Center and Hadassah Hospital in Jerusalem. 17, 18 Heterogeneity in diagnoses and disease states complicate the comparative value of these conditioning strategies but emphasizes the need for prospective comparative trials in defined risk populations.
Nonrelapse mortality was modest and did not differ between Flu or Clad-containing conditioning regimens. Analysis suggests that factors predictive of peritransplant toxicity after conventional transplant may also predict for nonrelapse mortality after these reduced intensity and modestly safer treatment approaches. Although both agents are profoundly immunosuppressive, we observed similar and persisting poor thymic output of TREC þ T lymphocytes to 1 year for patients treated with either the Flu or Clad regimen. A recent report 19 suggested modest recovery of TREC þ T cells after reduced intensity conditioning with Flu although TREC þ T-cell recovery was significantly delayed in patients with chronic GVHD or those receiving myeloablative conditioning with TBI.
The ideal strategy for reduced-intensity conditioning might tailor the disease risk and sensitivity to an immunologically based graft-versus-tumor effect as well as patient comorbidity factors into a risk-adapted array of conditioning regimen intensities. Older or more frail patients as well as those with more graft-versus-leukemia/ lymphoma (GVL) sensitive illnesses (i.e., CML, CLL, or follicular lymphoma) may benefit most from grafts using the lowest intensity regimens such as Flu plus TBI 200 cGy. More resistant illnesses (i.e., high-risk AML or MDS) may be best-controlled using anti-neoplastic conditioning of greater intensity, if still safely tolerated and not associated with excess nonrelapse mortality. Prospectively designed comparisons to validate the promising extensive phase II data already reported will help resolve these distinctions and guide investigators in tailoring the conditioning intensity to the recipient and to their cancer.
